Skip to Content

Gadopentetate Dimeglumine Dosage

Medically reviewed on July 24, 2018.

Applies to the following strengths: 46.9%

Usual Adult Dose for CNS Magnetic Resonance Imaging

0.1 mmol/kg (0.2 mL/kg) as a rapid bolus intravenous injection, at a rate not to exceed 10 mL per 15 seconds. Dosing for patients in excess of 286 pounds has not been studied. To ensure complete injection of the medium, the injection should be followed by a saline flush of at least 5 mL.

Usual Adult Dose for Vascular Magnetic Resonance Imaging

0.1 mmol/kg (0.2 mL/kg) as a rapid bolus intravenous injection, at a rate not to exceed 10 mL per 15 seconds. Dosing for patients in excess of 286 pounds has not been studied. To ensure complete injection of the medium, the injection should be followed by a saline flush of at least 5 mL.

Usual Pediatric Dose for CNS Magnetic Resonance Imaging

2 years to 18 years of age: 0.1 mmol/kg (0.2 mL/kg) as a rapid bolus intravenous injection, at a rate not to exceed 10 mL per 15 seconds. Dosing for patients in excess of 286 pounds has not been studied. To ensure complete injection of the medium, the injection should be followed by a saline flush of at least 5 mL.

Usual Pediatric Dose for Vascular Magnetic Resonance Imaging

2 years to 18 years of age: 0.1 mmol/kg (0.2 mL/kg) as a rapid bolus intravenous injection, at a rate not to exceed 10 mL per 15 seconds. Dosing for patients in excess of 286 pounds has not been studied. To ensure complete injection of the medium, the injection should be followed by a saline flush of at least 5 mL.

Renal Dose Adjustments

No adjustment recommended

Liver Dose Adjustments

No adjustment recommended

Precautions

US BOXED WARNINGS:
-NEPHROGENIC SYSTEMIC FIBROSIS (NSF): Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of GBCAs in such patients unless the diagnostic information is essential and not available with noncontrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle, and internal organs. Do not administer to patients with chronic, severe kidney disease (GFR less than 30 mL/min/1.73 m2) or acute kidney injury. Patients should be screened for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (e.g., greater than 60 years of age, hypertension, or diabetes), estimate the GFR through laboratory testing. Do not exceed the recommended dose and allow a sufficient period of time for elimination of the drug from the body prior to any readministration.

Safety and efficacy have not been established in patients younger than 2 years.

Consult WARNINGS section for additional precautions.

Dialysis

No adjustment recommended

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide